This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

McKesson Launches Takeover Offer For Remaining Celesio Shares

McKesson Corporation (NYSE:MCK), a leading North American healthcare services and information technology company, announced today that McKesson has launched a voluntary public takeover offer (“Takeover Offer”) for the remaining outstanding shares of Celesio AG (“Celesio”) through its indirect wholly-owned subsidiary Dragonfly GmbH & Co. KGaA. There are no closing conditions in relation to the Takeover Offer. McKesson currently exceeds 75% ownership of Celesio shares on a fully diluted basis.

The publication of the offer document for the Takeover Offer has been approved by the Bundesanstalt für Finanzdienstleistungsaufsicht and is now available on www.GlobalHealthcareLeader.com in German and in an English translation. Celesio shareholders can now accept the Takeover Offer and tender their shares in Celesio at the offer price of €23.50 per share. The initial acceptance period will end on April 2, 2014 at 24:00 (CET) / 18:00 (EST) and will be followed by an additional two-week acceptance period following the publication of the results of Takeover Offer.

About McKesson Corporation

McKesson Corporation, currently ranked 14 th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. McKesson partners with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit www.mckesson.com.

Disclaimer

This press release is for information purposes only and does not constitute an invitation to make an offer to sell any shares in Celesio AG (“ Celesio Shares”), a company organized under the laws of Germany (“ Celesio”). This press release does not constitute an offer to purchase Celesio Shares and is not for the purposes of making any representations or entering into any other binding legal commitments.

An offer to purchase Celesio Shares (“ Takeover Offer”) is solely made by the offer document published by Dragonfly GmbH & Co. KG (“ Dragonfly”), a wholly-owned subsidiary of McKesson Corporation (“ McKesson”), on February 28, 2014 and is exclusively subject to the offer document’s terms and conditions. The terms and conditions contained in the offer document may differ from the general information described in this press release.

Investors and shareholders of Celesio are strongly advised to read the relevant documents regarding the Takeover Offer because they contain important information. Investors and shareholders of Celesio can obtain these documents at the website http://www.GlobalHealthcareLeader.com. The offer document is also available free of charge at Deutsche Bank Aktiengesellschaft, TSS/Global Equity Services, Post-IPO Services, Taunusanlage 12, 60325 Frankfurt am Main, Germany, fax: +49 (0)69 910-38794, e-mail: dct.tender-offers@db.com and will be mailed to investors and shareholders of Celesio free of charge upon request.

Shareholders of Celesio are strongly recommended to seek independent advice, where appropriate, in order to reach an informed decision in respect of the content of the offer document and with regard to the Takeover Offer.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs